Montreal-based Inversago Pharma is developing a portfolio of peripherally-acting cannabinoid receptor-1 (CB1 ... are undergoing preclinical work for type 1 diabetes and diabetic nephropathy.

The drug, known as VIP36, targets the body's cannabinoid receptor type 1 (CB1). It was found to be effective in three ...